Lynsey Flynn
Payments from drug & device makers
Across 155 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$497
- AbbVie$287
- AstraZeneca$251
- Lilly USA, LLC$230
- Astellas Pharma US Inc$173
- Alkermes, Inc.$170
- plus $779 from 20 others
What the payments were for
- Food & beverage$2,22793%
- Education$1607%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 44 | $497 |
| AbbVie | 16 | $287 |
| AstraZeneca | 13 | $251 |
| Lilly USA, LLC | 16 | $230 |
| Astellas Pharma US Inc | 3 | $173 |
| Alkermes, Inc. | 8 | $170 |
| Sunovion Pharmaceuticals Inc. | 13 | $130 |
| Amgen | 7 | $130 |
| Novo Nordisk | 5 | $76 |
| Boehringer Ingelheim | 4 | $51 |
| Dexcom, Inc. | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Genentech USA, Inc. | 3 | $36 |
| Philips North America LLC | 2 | $31 |
| Bayer | 2 | $30 |
| Grifols USA, LLC | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $25 |
| Shield Therapeutics Inc | 1 | $23 |
| GSK | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Digestive Care, Inc. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Pfizer | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
How this compares
$2,387 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $44,288 |
| MounjaroTirzepatide | 30 | $37,882 |
| EliquisApixaban | 33 | $28,490 |
| JardianceEmpagliflozin | 27 | $23,878 |
| FarxigaDapagliflozin Propanediol | 17 | $22,724 |
| JanuviaSitagliptin Phosphate | 13 | $21,582 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $13,064 |
| XareltoRivaroxaban | 16 | $8,579 |
| MyrbetriqMirabegron | 15 | $8,207 |
| Repatha SureclickEvolocumab | 14 | $7,635 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,990 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,606 |
| Ondansetron Hcl | 15 | $1,598 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,177 |
| Levothyroxine Sodium | 122 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $76 | $44,28834 claims |
| Lilly USA, LLCMounjaro | $230 | $37,88230 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $51 | $36,94241 claims |
| PfizerEliquis | $15 | $28,49033 claims |
| AstraZenecaFarxiga | $251 | $22,72417 claims |
| Astellas Pharma US IncMyrbetriq | $173 | $8,20715 claims |
| GSKArnuity Ellipta | $22 | $2,60612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.
Other family in Nancy
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.